

**beclometasone dipropionate  
(Clenil Modulite)**

**(No. 177/05)**

**Trinity-Chiesi Pharmaceuticals Ltd**

**Product Update**

8 April, 2005 (*Distribution deferred until July 06, pending product launch*)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

The Clenil Modulite<sup>®</sup> range of inhalers is accepted for use in NHS Scotland for the prophylactic management of mild, moderate or severe asthma in adults or children.

They provide chlorofluorocarbon (CFC)-free inhalers with dose equivalence to CFC-containing inhalers. The cost is similar to another (CFC)-free inhaler, however doses are not equivalent to the other CFC-free inhaler product currently available.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 30 June 2006.*

**Vice Chairman  
Scottish Medicines Consortium**